A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2011 by Can-Fite BioPharma.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by (Responsible Party):
Can-Fite BioPharma
ClinicalTrials.gov Identifier:
NCT00790218
First received: November 11, 2008
Last updated: March 1, 2012
Last verified: August 2011
  Purpose

This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer. Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily basis. Treatment will be assessed for adverse effects and for effects on the tumor.


Condition Intervention Phase
Hepatocellular Carcinoma
Drug: CF102
Phase 1
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1-2, Open-label, Dose-escalation Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Orally Administered CF102 in Patients With Advanced Hepatocellular Carcinoma

Resource links provided by NLM:


Further study details as provided by Can-Fite BioPharma:

Primary Outcome Measures:
  • Dose limiting toxicity and maximum tolerated dose [ Time Frame: Continuous ] [ Designated as safety issue: Yes ]
  • Repeat-dose pharmacokinetic behavior of CF102 [ Time Frame: 1 month ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Therapeutic effect of CF102 in hepatocellular carcinoma [ Time Frame: Every 2 months ] [ Designated as safety issue: No ]
  • Relationship between biomarkers of peripheral blood mononuclear cell (PBMC) adenosine A3 receptor (A3AR) expression and clinical effects of CF102 [ Time Frame: Baseline ] [ Designated as safety issue: No ]

Estimated Enrollment: 20
Study Start Date: February 2009
Estimated Study Completion Date: December 2012
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: CF102 Drug: CF102
CF102 capsules twice daily by mouth
Other Names:
  • 2-Chloro-N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide
  • Cl-IB-MECA

Detailed Description:

This is a multicenter, open-label, non-randomized, dose-escalation study, to be conducted in 2 phases: a dose-escalation phase, to determine the MTD of CF102 and to evaluate its safety/tolerability, PK, pharmacodynamic, and preliminary clinical activity; and a dose-confirmation phase, which will be a cohort expansion at or below the MTD (ie, the RP2D) of CF102. Subjects will be treated with oral doses of CF102 in consecutive, 28-day cycles. The initial dose of CF102 will be 1 mg twice daily (BID), with subsequent escalations to 5 and 25 mg BID, unless limited by toxicity. Subjects will be evaluated weekly for the first cycle, every 2 weeks for Cycles 2 and 3, and at the end of each subsequent cycle, up to 6 cycles of CF102 treatment. Subjects will return for a follow-up visit 28 days after completion of the last dose of study drug.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Diagnosis of HCC:

    • For patients without underlying cirrhosis, diagnosis of HCC documented by cytology and/or histology
    • For patients with underlying cirrhosis, diagnosis of HCC established according to the American Association for the Study of Liver Diseases Practice Guideline algorithm (Appendix V).
  2. HCC is advanced, refractory, or metastatic, and no standard therapies are expected to be curative.
  3. At least 18 years of age.
  4. For subjects in the dose-confirmation (RP2D) phase only: Measurable disease, using Response Evaluation Criteria in Solid Tumors (RECIST, Appendix IV). (Note that a lesion that has been subjected to radiotherapy or chemoembolization cannot be used as a target lesion.)
  5. Eastern Collaborative Oncology Group (ECOG) performance status (PS) of 0, 1, or 2 at baseline.
  6. The following laboratory values must be documented within 3 days prior to initiation of study drug:

    • Absolute neutrophil count (ANC) greater than or equal to 1 x 109/L
    • Platelet count greater than or equal to 50 x 109/L
    • Serum creatinine less than or equal to 2.0 mg/dL
    • Aspartic aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 × upper limit of normal.
    • Total bilirubin ≤ 3.0 mg/dL.
    • Serum albumin ≥ 3.0 g/dL.
    • International normalized ratio (INR) ≤ 2.3.
  7. Esophageal bleeding and varices, if present, have been sclerosed or banded, and no bleeding episodes have occurred during the prior 6 months.
  8. Life expectancy of ≥ 12 weeks.
  9. For women of childbearing potential, negative serum pregnancy test result.
  10. Absence of active malignancy other than HCC within 2 years of entry, with the exception of basal cell carcinoma and squamous cell carcinoma of the skin.
  11. Provide written informed consent to participate.
  12. Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other study related procedures.

    -

Exclusion Criteria:

  1. Any chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, corticosteroids > 20 mg/day prednisone or equivalent, or growth factor treatment (e.g., erythropoietin) within 14 days prior to initiation of study drug.
  2. Major surgery or radiation therapy within 28 days prior to initiation of study drug.
  3. Severe liver dysfunction (Child-Pugh Class C or hepatic encephalopathy).
  4. Active infection requiring systemic therapy.
  5. Uncontrolled congestive heart failure (New York Heart Association Classification 3 or 4), angina, myocardial infarction, cerebrovascular accident, coronary/peripheral artery bypass graft surgery, transient ischemic attack, or pulmonary embolism within 3 months prior to initiation of study drug.
  6. History of or ongoing cardiac dysrhythmias requiring treatment, atrial fibrillation of any grade, or persistent prolongation of the QTc (Fridericia) interval to > 450 msec for males or > 470 msec for females.
  7. Pregnant or lactating female.
  8. Women of childbearing potential, unless they agree to use dual contraceptive methods which, in the opinion of the Principal Investigator (PI), are effective and adequate for that patient's circumstances while on study drug.
  9. Men who partner with a woman of childbearing potential, unless they agree to use effective, dual contraceptive methods (i.e., a condom, with female partner using oral, injectable, or barrier method) while on study drug.
  10. Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness.
  11. Any severe, acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, may interfere with the informed consent process and/or with compliance with the requirements of the study, or may interfere with the interpretation of study results and, in the investigator's opinion, would make the patient inappropriate for entry into this study.

    -

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00790218

Locations
Israel
Rabin Medical Center
Tel Aviv, Israel
Sponsors and Collaborators
Can-Fite BioPharma
Investigators
Study Director: Michael H Silverman, MD Can-Fite BioPharma Ltd
Principal Investigator: Salomon Shtemmer, MD Rabin Medical Center
  More Information

Additional Information:
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Can-Fite BioPharma
ClinicalTrials.gov Identifier: NCT00790218     History of Changes
Other Study ID Numbers: CF102-102HCC
Study First Received: November 11, 2008
Last Updated: March 1, 2012
Health Authority: United States: Food and Drug Administration
Israel: Ministry of Health

Keywords provided by Can-Fite BioPharma:
Hepatocellular carcinoma
Hepatoma
HCC

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Hepatocellular
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Adenocarcinoma
Liver Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases

ClinicalTrials.gov processed this record on July 20, 2014